Cancer Gene Mutation Analysis by Exome Sequencing (EXaCT-1)
Whole Exome Sequencing (WES) has become a fast and relatively cost-efficient way to interrogate a large area of the genome, enabling identification of gene variations and mutations that can lead to cancer. This is especially beneficial for advanced stage cancer patients, where other treatments have failed, as it can detect mutations that the less comprehensive panel tests might miss. On October 28, 2015, EIPM became the first to be granted approval from the NYSDOH for the first Whole Exome Sequencing test for cancer, we named EXaCT-1. The EXaCT-1 Whole Exome Sequencing (WES) test is a Next Generation Sequencing (NGS) assay that interrogates tumor DNA, detecting single nucleotides variants, indels, and copy number alterations in a pair of patient-matched malignant and healthy specimens. The regions incorporated in the WES test include the coding areas of 21,522 human genes.
Ask your physician or oncologist whether ordering this test is right for you. For more information on EXaCT-1, visit our Department of Pathology website.